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The great success of therapeutic monoclonal antibodies has
fueled research toward mimicry of their binding sites and the
development of new strategies for peptide-based mimetics pro-
duction. Here, we describe a new combinatorial approach for
the production of peptidomimetics using the complementar-
ity-determining regions (CDRs) from gastrin17 (pyroEGP-
WLEEEEEAYGWMDF-NH2) antibodies as startingmaterial for
cyclic peptide synthesis in a microarray format. Gastrin17 is a
trophic factor in gastrointestinal tumors, including pancreatic
cancer, which makes it an interesting target for development of
therapeutic antibodies. Screening of microarrays containing
bicyclic peptidomimetics identified a high number of gastrin
binders. A strong correlation was observed between gastrin
binding and overall charge of the peptidomimetic. Most of
the best gastrin binders proceeded from CDRs containing
charged residues. In contrast, CDRs from high affinity antibod-
ies containingmostly neutral residues failed to yield good bind-
ers. Our experiments revealed essential differences in the mode
of antigen binding between CDR-derived peptidomimetics (Kd
values in micromolar range) and the parental monoclonal anti-
bodies (Kd values in nanomolar range). However, chemically
derived peptidomimetics from gastrin binders were very effective
in gastrin neutralization studies using cell-based assays, yielding a
neutralizing activity in pancreatic tumoral cell lines comparable
with that of gastrin-specific monoclonal antibodies. These data
support the use of combinatorial CDR-peptide microarrays as a
tool for thedevelopment of anewgenerationof chemically synthe-
sized cyclic peptidomimetics with functional activity.
Antibody-based therapeutics have emerged as important
components of therapies for an increasing number of debilitat-
ing and life-threatening diseases (1–3). The unique properties
of antibodies provide a source of inspiration for active research
in antibody engineering. Over the years, a wide range of anti-
body fragments (Fab, scFv)8 and variants (dia-, tria-, tetra-,
mini-bodies, single-domain antibodies, intramers, etc.) have
been developed (4–8), some of which are used today in clinical
therapies (9, 10). One step further in downsizing the antibody
molecule is to use peptides derived from one or more of the
six hypervariable loops, or “complementarity-determining
regions” (CDRs; Fig. 1A) (11). Mutational analysis of antibody-
combining sites suggests that only a subset of interface contact
residues is essential for binding (12, 13). Several publications
have appeared since the first report on CDR-derived peptides
(14), with bioactivities even approaching those of the parent
antibodies in a few cases. Heap et al. (15) reported a cyclic
17-mer peptide derived from the H3 CDR of an anti-gp120
mAbwith only 37-fold lower affinity (KD 7.5 nM versus 0.2 nM
for the mAb) and 32-fold lower HIV-1 neutralizing capacity.
Some studies also use a rational design-based approach tomake
antibody-like binders, with remarkably high in vivo activities
(16, 17).
In most cases, however, CDR-derived peptides showed a
much lower activity than the parental antibodies, even though
the 1:1 affinities were reported to be in the same range (18–20).
For example, IC50 values for the inhibition of viral reproduction
were 350-fold higher (7 M) for a peptide derived from the
anti-CD4mAb ST40 (20 nM), whereas the reported affinity of
the peptide for CD4 was only3-fold lower than the antibody
(KD 900 pM versus 370 pM) (18). Similarly, partial inhibition of
formation of an idiotypic mAb1mAb2 complex (KD 1 nM)
occurred only at 6.6 M for the best peptide, whereas the
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reported difference in affinities was only 10 (19). Obviously,
this raises concerns about potential differences in the antigen-
binding mechanism between antibodies and corresponding
mimics.
The peptide hormone gastrin is an important growth factor
for gastric, pancreatic, and other gastrointestinal malignancies
(21–25) through autocrine, paracrine, and endocrine mecha-
nisms (26). Recently, gastrin has been described as an essential
cofactor for gastric corpus carcinogenesis (27). Due to this fact,
gastrin is considered an important therapeutic target for gas-
trointestinal cancers (28, 29). In fact, an anti-G17 vaccine,
which is producing a significant increase in the survival time of
patients, is being used in phase III clinical trials for pancreatic
cancer and in phase II for colorectal and gastric cancer patients
(30).
Here, we report the use of a synthetic combinatorial strategy
for the production of CDR-derived peptidomimetics targeting
the tumor antigen G17 (pyroEGPWLEEEEEAYGWMDF-
NH2). We describe synthesis and high throughput screening of
10,000 mimetics from five anti-G17 antibodies with KD val-
ues ranging from 500 pM to 1 M. The most active peptido-
mimetics neutralized G17 in an effective manner (IC50 50
M) in cell-based proliferation assays using colorectal Colo320
WT and pancreatic BxPc3 tumoral cells (31, 32).
EXPERIMENTAL PROCEDURES
Peptides and CDR Peptidomimetics—G17, G17 variants, and
CDR peptidomimetics were provided by Pepscan Therapeutics
(Lelystad, The Netherlands). T2 (,-dibromoxylene) and T3
(2,4,6-tris(bromomethyl)mesitylene) were purchased from
Sigma.
Synthesis of Bicyclic Peptidomimetic for High Throughput
Screening Studies—Synthesis of peptide microarrays on
polypropylene support was performed as described previously
(33, 34). After side chain deprotection using trifluoroacetic acid
and scavengers, the microarrays were washed with excess of
milliQ/H2O (five times for 10 min) and treated with a 0.5 mM
solution of T3 in a 1:1 mixture of acetonitrile/NH4HCO3 (20
mM, pH 7.8) for 45–60min to afford the corresponding chem-
ical linkage of peptides onto scaffolds-peptides (format
*CT(X)nCT(X)nCT-resin, where n  4–6 and “CT” represents
cysteines that are chemically linked via the T3 scaffold to two
other CT values). Finally, the microarrays were washed with
excess of acetonitrile/H2O, 1:1 (three times for 10 min), and
sonicated in disrupt-buffer (1% SDS, 0.1% -mercaptoethanol
in PBS at 70 °C for 30 min, followed by sonication in milliQ/
H2O for another 45 min). Binding studies with G17 were per-
formed as described before (33, 34). Complete methods of bulk
synthesis of linear peptides, backbone-cyclized peptides, and
CDR-derivedpeptidomimics are shownas supplementalmaterial.
Liquid Chromatography-Mass Spectrometry Characteriza-
tion of 1–5 Mimetics—Chromatographic analysis of the pep-
tides was performed on a C18 reversed-phase high perform-
ance liquid chromatography column, either using a DeltaPack
C18 (3.9  150 mm (dxl), 5-m particle size, 100-Å pore size;
Waters) or an Atlantis C18 column (4.6  50 mm (dxl), 3-m
particle size; Waters) with a linear gradient of 5–65% solvent B
in solvent A over 10 min (6%/min) (solvent A 0.05% trifluo-
roacetic acid in H2O; solvent B 0.05% trifluoroacetic acid in
acetonitrile). Alternatively, analysis was performed on an
Acquity UPLC (Waters) using an RP-18 preparative “BEH” col-
umn (2.1  50 inner diameter, 1.7-mm particle size, Waters)
with a linearABgradient (5–55% solvent B, 25% solvent B/min),
where solvent A was 0.05% trifluoroacetic acid in water and
solvent B was 0.05% trifluoroacetic acid in acetonitrile. The
molecular weight of the peptides was determined by electro-
spray ionization on a Waters ZQ or a Quattro II SG (Micro-
mass, UK) mass spectrometer. In all cases, the experimental
and the calculated molecular mass (MM) of the peptides was
equivalent (maximum variation0.9 Da).
Preparation and Screening of Peptide/CDR Mimic Micro-
arrays—Microarrays displaying CDR mimetics were prepared
as described previously (33, 34). Screening formAbbindingwas
performed using knownmethodologies (34). G17 binding stud-
ies with CDR mimic arrays were performed using biotinylated
G17 (pyroEGPWLEEEEEAYGWMDFK(biotin); 10 g/ml) in
PBS/Tween 80, followed by conjugation with streptavidin per-
oxidase (Southern Biotech; 1:1000 dilution in 5% bovine serum
albumin/horse serum) following the standard procedure (34).
Surface Plasmon Resonance (SPR) Studies—HBS-EP (10 mM
HEPES, pH 7.4, 150mMNaCl, 3.4mMNaEDTA, 0.005% surfac-
tant P-20) was used as running and dilution buffer for experi-
ments involving CDR mimics and PBS containing 0.005% sur-
factant P-20 for experiments with themAbs/scFvs. CM5 sensor
surfaces (BR-1000-14, Biacore AB) were used, and interactions
were monitored at 25 °C. Cysteine-extended G17 was immobi-
lized using thiol-coupling chemistry. The immobilization level
of G17 and variants was adjusted to avoid mass transfer limita-
tions as follows: less than 10 response units for analyzing inter-
actions with the mAbs and above 1000 response units for the
CDRmimics. The reference surface was treated similarly to the
ligand surfaces, except that peptide injection was omitted. SPR
responses of the peptidomimetics were expressed as percent of
the theoretical binding capacity of the surfaces (%Rmax) assum-
ing a 1:1 interaction (Rmax  RligandMManalyte/MMligand).
This allowed us to normalize responses for differences in ligand
immobilization levels (Rligand) and in MM of injected analytes
(MManalyte).
Screening of CDRMimics—Stock solutions of CDRmimics in
H2O (1.0 mM) were diluted with HBS-EP to 1–100 M. In case
of solubility problems, stock solutions were prepared in 10–20
mM NaOH. Before injection, solutions were centrifuged and
filtered through a 0.22-m MILLEX GP Millipore filter. CDR
mimics were injected at 20 l/min flow rate. Sensor surfaces
were regenerated with 10 l of 50–100 mM HCl.
Determination of Binding Affinities—Analytes (mAb and
CDRmimics) were injected over G17 and corresponding refer-
ence surfaces at 5–7 different concentrations with a 30-l/min
flow rate for 60 s (CDR mimics) and 120 s(mAb). The surfaces
were regenerated by a 10-l injection of 100 mM HCl.
BIAevaluation 3.2 software was used for data evaluation.
G17-dependent Colo320 WT and BxPc3 Cell Proliferation
Assays—Experiments were carried out following established
procedures (35, 36). Briefly, Colo320WT cells were plated onto
96-well tissue culture plates at a density of 104 cells/well in
RPMI 1640 medium supplemented with 10% fetal bovine
CDR-derived Peptidomimetics
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serum, antibiotics, and geneticin in duplicate. Once attached,
cells werewashedwith PBS and culturedwith different concen-
trations of peptidomimetics at five different concentrations
(ranging 200 to 12.5M) in RPMI 1640medium containing 5
1010 mol/liter of G17, geneticin, and antibiotics for 72 h at
37 °C in 5%CO2. After removing themedium, cell proliferation
was scored by staining cells with 100l of the chromogenic dye
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(Sigma) at a final concentration of 1 mg/ml in RPMI 1640
medium. The cells were further incubated for 1 h at 37 °C and
5% CO2. Then, 100 l of DMSO (Sigma) were added to each
well. Absorbance was read at 570 nm. Cell viability is repre-
sented as the ratio of absorbance between peptidomimetics-,
scFv-, or mAb-treated cells and nontreated cells, expressed as a
percentage. The same assay was used for BxPc3 pancreatic ade-
nocarcinoma cell line with minor modifications. BxPc3 cells
were cultured at a density of 5 103 cells per well in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine
serum and antibiotics. The next day, the cells were washedwith
PBS and cultured in Dulbecco’s modified Eagle’s medium con-
taining antibiotics and the peptidomimetics, scFvs or mAbs, in
the same conditions as the Colo320 WT cells. All the experi-
ments were performed in duplicate and repeated three times.
RESULTS
In previous studies, we described the production of a wide
collection of scFvs andmonoclonal antibodieswith gastrin neu-
tralizing activity (35, 36). Here, microarrays of bicyclic peptido-
mimetics (Fig. 1B and Table 1) were prepared by using the CDR
sequences of three anti-G17 murine mAbs (189DB3, 243BA5,
and 23CA8), which bind G17 with
Kd,1 between 0.54 and 11.3 nM, as
measured by SPR (Fig. 2A), as start-
ing material. Chemical synthesis of
the peptidomimetics at the mi-
croarray surface was performed as
follows. First, we synthesized linear
peptides composed of two CDR
fragments, separated by three cys-
teines (format, C-CDRA-C-CDRB-
C-resin, where C represents cys-
teines interconnected via either a
T3 or T2 scaffold; Fig. 2B). Subse-
quently, all three cysteines were
chemically linked to a synthetic
“platform” using enzyme-linked
immunosorbent assay technology
(Fig. 1B) (37), whereby the CDR
fragments become cyclized to struc-
turally mimic the CDRs as closely as
possible. The microarrays cover
every possible combination of pep-
tide fragments (4–6-mers) derived
from the H2, H3, and L3 CDR
sequences (Fig. 2B). The total num-
ber of peptidomimetics generated
in this way was 400–800 for each
mAb.
G17 Binding of Peptidomimetics Derived from Anti-G17
mAbs—Screening of the microarrays for G17 binding showed
that the number of hits differed substantially among the parent
antibodies (Fig. 2,C–E). Little to no binding (A450 nm1.0) was
observed for peptidomimetics derived from the CDRs of mAbs
23CA8 and 243BA5 (Fig. 2, C and D), most notably, those with
the highest affinities for G17 (Kd1 3.0 and 0.54 nM). Instead,
15–20% of the peptidomimetics derived from mAb 189DB3
(Kd1  11.3 nM) showed strong binding of G17 (A450 nm 2.0;
Fig. 2E). Sequence analysis showed that strong binders were
mostly derived from the H2 (VASIKSGGST) and L3 (VQGTH-
FPRTF) CDRs, whereas H3 CDR (RSDRYDEDY) mainly gave
rise to nonbinders. Reproducibility of the chemical synthesis
and G17 screening procedure was high. Resynthesis and
screening of a subset (125) of the 189DB3-library showed
excellent correlation with the original data (Fig. 3). Six out of 10
of the best binders of the duplicated dataset were also present in
the top 10 of the original set and vice versa. Moreover, 10 of 10
best binders in each set were among the 28 best binders of the
other dataset. Control binding studies with linear (no T3 pres-
ent, cysteines replaced by serines) or single loop mimetics
(C-CDR-C-resin; T2 instead of T3) clearly showed that G17
binding was significantly weakened (A450 nm 0.5 and 1.0,
respectively).
Correlation between Gastrin Binding and Overall Charge of
the Peptidomimetics—Further analysis of the 189DB3 dataset
revealed a strong correlation between binding and the overall
charge of the peptidomimetics (Fig. 4A). Themajority of strong
binders (99%withA450 nm1.0) carry an overall positive charge
(1 or2). The five strongest G17 binders of the 189DB3 data-
FIGURE 1. Structure of antibody and CDR-derived peptidomimetics. A, schematic representation of the
protein domain structure in antibodies (constant heavy chain (CH), constant light chain (CL), variable heavy
chain (VH), and variable light chain (VL)), with amplified structural details for the variable fragment (Fv: CDR1,
CDR2, and CDR3 of VH and VL chain). B, monocyclic, bicyclic, and tricyclic peptidomimetics are depicted
together with molecular details for the scaffolds (T2 and T3) used in Chemical LInkage of Peptides onto Scaf-
folds methodology.
CDR-derived Peptidomimetics
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set all carry a2 charge (Fig. 4E), the highest possible charge in
this library (885 compounds ofwhich 18.1%have2, 29.6%1,
18.6% have 0, and 33.8% have 1 to 6 net charge). In sharp
contrast to this, the worst five binders in this set were either
negatively charged (3 of 5) or neutral (2 of 5). The importance of
charge in G17 binding also explains why peptidomimetics
derived from theCDRs of either 243BA5 or 23CA8 did not bind
G17 (Fig. 2, C and D). In these libraries, not a single mimetic
from the 1000 peptidomimetics investigated carries a net
positive charge.
Efforts to correlate G17 binding to the presence of single
amino acid types clearly showed that A450 nm values increased
with the number of lysines and decreased with the number of
aspartic acids, with little influence of noncharged amino acids.
However, the number of arginines failed to correlate well with
G17 binding (data not shown), which seems due to the fact that
two of three of the arginines in the 189DB3 dataset are located
within H3 CDR (97RSDRYDEDY105) including four acidic
(Asp/Glu) residues. To address this issue in more detail, we
synthesized a microarray of 1000 peptidomimetics derived
from scFvs PAR10C3 and PAR10D10 that have only weak affin-
ity for G17 (KD for G17 1 M), but the H3 and L3 CDRs of
which contain 5–8 Lys/Arg residues and no Asp/Glu residues
(Fig. 2A) (38). As expected, 90% of the peptidomimetics
showed strong binding to G17 (Fig. 2, F and G) with a clearly
positive correlation between A450 nm values, overall charges,
and number of Lys/Arg residues present (Fig. 4, B and C).
Replacement studies for peptidomimetics with high affinity
for G17 (top 5, see Fig. 4D) also confirm the importance of
charge for G17 binding. For example, replacement of each res-
idue in CTKSGGSCTVASIKCT-resin (1e) by Asp strongly
impeded binding for Lys-1, Lys-10, and Ile-9 (90, 80, and 70%
binding decrease, respectively), but little for amino acids more
remote (i.e.2 residues) from these (20% decrease in binding
for Gly-4 to Ala-7). Replacement of Lys-10 in 1e by the other 19
natural amino acids showed the strongest effect for replace-
ment by Asp andGlu (90% reduction), a lesser effect for other
amino acids (50–80%), and none for Arg.
Soluble CDR-derived Peptidomimetics Bind Gastrin 17—We
also studied binding of a representative set of soluble CDR-
TABLE 1
Amino acid sequence, PEPSCAN, and SPR data for CDR peptidomimetics
Sequence information and binding data for G17 CDR 1–5 peptidomimetics are provided. Column A, PEPSCAN, shows peptide screening, and column B shows SPR. nr
indicates number.
aCT represents cysteines interconnected via either a T3 or a T2 scaffold; all linear peptides were acetylated at the N terminus and have a C-terminal amide (CONH2); “c[XXXX]”
represents backbone-cyclized peptides.
b S represents serines substituting (T3-connected) cysteines in order to study the influence of T3/T2 on G17 binding.
c G17 indicates pyro-EGPWLEEEEEAYGWMDF; GnRH indicates pyro-EHWSYGLRPG (gonadotropin-releasing hormone); HEL indicates hen egg white lysozyme; nd
indicates not determined; na indicates not applicable. *, peptidomimetics tested in in vitro neutralization assays.
CDR-derived Peptidomimetics
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derived peptidomimetics to surface-immobilized G17 using
SPR (Fig. 4E). A total of 12 soluble peptidomimetics derived
from 189DB3was synthesized (supplemental material), includ-
ing the top 5 binders in microarrays (1a–e) plus 7 different
CDR combinations (1f–1l). Measurable binding at 50 M was
clearly observed for all mimetics with 2 charge (1a–e and
1g–h; %Rmax between 3.3 and 12.4).Mimetic 1fwith1 charge
showed only weak binding (%Rmax 2.3), even though it bound
strongly to G17 (A450 nm  2.65) when immobilized at the
microarray surface. The requirement for a positive charge
would also explain the absence of binding to G17 in SPR
(%Rmax 0) formimic1i, one of the fewmimicswith charge0
that showed G17 binding in microarrays. Like 1i, none of the
other threemimetics (1j–l) with1 charge showed any binding
to surface-immobilized G17 in SPR. Together, these data con-
firm G17 binding for 7 of 9 peptidomimetics derived from
189DB3, whereas 2 of 9 binders investigated appeared to be
false positives.
Binding to surface-immobilized G17 in SPR was also con-
firmed for the top 3 binders of the PAR10C3 and PAR10D10
library (1m–1r; Fig. 4E). These data again highlighted the
importance of overall charge, but the data also visualized large
differences in G17 binding strength among the best G17 bind-
ing mimics, most likely as a result of solid-phase effects (multi-
valency). Moreover, it was found that this binding was
decreased by 15–50% upon increasing the NaCl concentration
from 150 to 400 mM, which hints at significant electrostatic
interactions.
G17 Binding Affinity Evaluation by SPR—In theory, 1:1 bind-
ing affinities (KD values) can be evaluated by SPR only if the
injected compounds are homogeneous and monomeric. How-
ever, most binding curves typically showed complex kinetics
(multiphasic and slow injection/post-injection phases, Req
100% Rmax), indicative of the presence of heterogeneous
material and/or multimeric interactions (Fig. 5A and B, and
Table 1). Such binding curves were observed for bicyclic
mimetic 1 (n/p/v/w; Fig. 5B) and tricyclic mimetics 2a and 2b
(Fig. 5A). The latter cover H2, H3, and L3 CDR loop sequences
of 189DB3 and have a cyclic backbone rather than a linear back-
bone (for 1d/1h; Fig. 1B).
Binding curves for the 2 charged mimetics 1d and 1h
(189DB3), 1q (PAR10D10), and 1s (D1.3) were typical of low
affinity 1:1 interaction/fast complex formation and dissociation
with stable equilibrium responses (Req). Theoretically, KD val-
ues can be calculated from the dependence of Req and [bycyclic
peptidomimetics], but data fitting approaches like these are
tentative when Req is still far below surface saturation (25%
Rmax) at [bycyclic peptidomimetics]max. Therefore,KD values in
the 100–500 M range were estimated for 1d and 1h by com-
paring experimental and simulated responses (data not shown).
FIGURE 2.High throughput G17 binding data for microarrays of overlapping CDR-derived bicyclic peptidomimetics. A, amino acid sequences for
the CDRs of five anti-G17 mAbs/scFvs  G17 affinity data as determined by SPR or enzyme-linked immunosorbent assay (only PAR10C3); gray areas
indicate CDR regions covered in microarray synthesis. B, experimental design of microarrays with overlapping bicyclic peptidomimetics (surface-
immobilized) derived from the H2, H3, and L3 CDRs of the five anti-G17 antibodies. C–G, A450 nm values for G17 binding to bicyclic peptidomimetics
derived from mAb 243BA5 (C), mAb 23CA8 (D), mAb 189DB3 (E), scFv PAR10C3 (F), and scFv PAR10D10 (G). Binding studies were performed with 10
g/ml of biotinylated G17 (pyroEGPWLEEEEEAYGWMDFK(biotin), followed by conjugation using peroxidase-labeled streptavidin at 1:1000 dilution. nr,
number.
CDR-derived Peptidomimetics
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SPR evaluation of the linear peptides 5a–c and monocycles
3a–c (linear and single loop controls of 1d/h and 2a/2b)
revealed that only 5c (H3/H2/L3 CDRs;3 charge) and 3c (L3
CDR only; 1 charge) showed measurable responses, with KD
values in the 100 M (5c) to 1 mM (3a) range (Table 1). Interac-
tion of the other controls with G17 was hardly detectable
(1.5% Rmax).
Evaluation of G17 Neutralizing Activity in BxPc3 and
Colo320WTCell-based Assays—Neutralizing activities of pep-
tidomimetics 1–5 for G17were evaluated in two different G17-
dependent cell proliferation assays (Colo320 WT and BxPc3
cell-based assay; Fig. 6) and compared with previous data
obtained with scFv and mAbs (35, 36). Experiments were per-
formed at five different concentrations, ranging from 200 to
12.5 M. Of all peptidomimetics 1–5, the tricyclic mimetic 2a
(3 charge) showed the highest neutralizing activity in both
assays (Fig. 6, A and C). The observed dose response was close
to perfect, and the IC50 values of 50 M in both assays were
only 30-fold higher than for the high affinitymAbs 243BA5 and
198CA8 (IC50 1.6M) (Fig. 6,B andD).Most striking was the
fact that removal of the T3 central core in 2a, completely abol-
ished the activity (see 4a in Fig. 6). The observed effect was
equally strong in both assays. Interestingly, mimic 2b displayed
a higher tendency for aggregate formation by SPR than 2a (Fig.
5A). Also, peptide 5c, the linear variant of 2a, showed activity in
both assays, despite the absence of T3. However, the dose
responses for 5c were poorer than 2a, for example.
Monocyclic peptidomimetics 3a and 3b showed neutralizing
activities only emerging at 200 M. Bicyclic 1h exhibited activ-
ity in the Colo320 WT cell assay down to 25 M, but a typical
dose response was not seen. In any case, the difference in activ-
ity between mono-cycles and bi-cycles peptidomimetics was
marginal. T3-less cyclic peptidomimetics 4a/b were not active
either in Colo320 WT or BxPc3 cell assays. Negative control
peptide 1x (4 charge) was totally silent in both assays, con-
firming the importance of positive charge also for G17 neutral-
izing activity.
DISCUSSION
Peptidomimetics consisting of one or more CDRs represent
the ultimate example of a miniaturized antibody (20, 39–42).
Antibodies are depicted as being oversized for the mere pur-
pose of antigen binding, and it has been suggested that the anti-
body-binding site could be downsized significantly without
major loss of binding affinity. This view is supported strongly by
virus-neutralizing data and tumor mouse models, which high-
lighted the potential therapeutic and diagnostic value of this
new class of drugs (15, 16, 43, 44). However, little is known
about the exact mechanism of production or whether CDR-
derived peptidomimetics bind the antigen in a similar or totally
differentmode as comparedwith the parent antibody. The high
throughput synthetic approach (10,000 compounds) in com-
bination with the use of a small peptide antigen (G17) and sys-
tematic amino acid replacements facilitated the binding analy-
sis to the level of individual amino acids.
Screening of microarrays with bicyclic peptidomimetics
showed that binding of G17 occurred exclusively for mimics
with multiple cationic residues (Arg/Lys) and a net charge0.
It seemed likely at first sight that these mimics recognize the
acidic G17 (6 charge) mainly via electrostatic attraction. A
very similar mode of binding was observed for scFvs with low
affinity for G17 (KD 1 M) (38). The high affinity antibodies
FIGURE 3. Sequences, overall charges, and A450 nm values for a subset (125 peptides) of the 189DB3microarray that was synthesized in duplicate to
address the reproducibility of themicroarray data. Bars corresponding to the top 10 binders in each set are in black to emphasize their position. Peptides
indicatedwithF (6 of 10) were also present in the top 10 binders of the duplicate set.Numbers next toF indicate the top 10 binders according to their A450 nm;
parentheses indicate their position in the other assay.
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seem to bind G17 via a totally different mechanism. Electro-
static interactions do not play a major role here, as judged from
the fact that residues most essential to binding (pyroEGPWL)
were all neutral (35). Moreover, the antibody CDRs include an
almost equal number of basic and acidic residues.
This mode of binding is not easily mimicked with CDR-de-
rived peptidomimetics, as deduced from the fact that none of
the peptidomimetics derived from mAbs 23CA8 and 243BA5
showed appreciable affinity for G17 (Fig. 2C). It is expected that
shape complementarity and specific H-bonding patterns
require a higher level of structural organization, where even
small changes will have high impact on binding. In this sense,
the grafting of CDR loops onto a synthetic scaffold can be com-
paredwith conventionalCDRgrafting for antibodyhumanization
purposes. The latter often leads to a reduction in affinity (45),
which has been associated with subtle conformational effects
within framework regions in the periphery of the antibody-com-
bining site (46). Transplantation of CDR fragments onto a syn-
thetic scaffold is clearlymore radical than grafting onto a structur-
ally homologous framework. It is therefore obvious that highly
specific, short range interactions will be lost and that, at best, only
the less specific electrostatic and/or hydrophobic driving forces
will be preserved. The latter can nevertheless provide a basic level
of affinity that can be enhanced by high throughput screening and
selection.The intrinsic conformational flexibility of peptidic loops
may even act favorably in this regard.
The CDR-derived peptidomimetics can be envisaged as an
exponent of primarily charge-driven binders. They seem to rec-
ognize essentially the presence and number of certain amino
acid types (charged, aromatic, and hydrophobic) rather than
well defined amino acid combinations. The multimeric nature
of the peptidomimeticG17 complexes also suggests a clear dif-
ference in binding mechanism. In microarrays, G17 binding is
likely the result ofmultivalent interactions, as judged from slow
dissociations (G17 binding was detectable after three 30-s
washes). In case of low affinity 1:1 complexes, binding should be
lost completely within seconds. Additional evidence comes
fromSPR studies, where the observed slowdissociation kinetics
(kd102 s1) could suggest high affinity 1:1 binding (Fig. 5B).
However, when high affinity complexes are formed, surface sat-
uration is expected within seconds upon injection of bicyclic
peptidomimetics at 50 M. The fact that this was not observed
FIGURE 4. Analysis of G17 binding strength of CDR-derived bicyclic peptidomimetics. A–C, correlation of G17 binding levels (A450 nm values) to overall
charge of bicyclic peptidomimetics derived from mAb 189DB3 (A), scFv PAR10C3 (B), and scFv PAR10D10 (C). D, complete Asp scan and Lys-10 replacement
analysis of bicyclic peptidomimetic 1e (CTKSGGSCTVASIKCT-T3) (derived frommAb 189DB3), showing the crucial role of charge in G17 recognition. E, compar-
ison of G17 binding levels (A450 nm) in PEPSCANmicroarrays and SPR (%Rmax, being 100% Rmaxwhen Req Rmax,calc) in relation to overall charge for someof the
best and worst G17 binders derived frommAb 189DB3, scFv PAR10C3, and scFv PAR10D10.
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further supports the occurrence of multimeric aggregates with
poorly defined structures and stoichiometries.
The results of our studies show interesting parallels with pre-
viously reported data, suggesting a general mechanism that can
be used for other antigens. For example, the HIV-neutralizing
“microantibody” (CDLIYYDYEEDYYFDYC; 7 Trp/Tyr/Phe, 6
Asp/Glu, 0 Arg/Lys, and 2 Leu/Ile, 17 residues in total)
described by Heap et al. (15) shows remarkably close resem-
blance to our target antigen G17 (4 Trp/Tyr/Phe, 6 Asp/Glu, 0
Arg/Lys, and 2 Leu/Met, 17 in total). Moreover, the target
epitope sequence on gp120 of HIV-1 (KRXXXIGPGR) is highly
reminiscent of some of the top 5 G17 binders (Fig. 4E). Simi-
larly, peptides reported by Greene and co-workers (41, 42) to
block gp120 binding to CD4 (e.g. FCYICEVEDQCY; (3 Tyr/
Phe, 3 Asp/Glu, 0 Arg/Lys, and 1 Ile) or inhibit proliferation of
overexpressing tumor cells (e.g. “aromatically modified”
FCDGFYACYMDV; (4 Tyr/Phe, 2 Asp, 0 Arg/Lys, and 2 Val/
Met) also have similar constitutions. Finally, a series of potent
synthetic receptors for platelet-derived growth factor and vas-
cular endothelial growth factor displaying very strong activity
in tumor suppression were described (16, 17, 43). The compo-
sition of the peptide loops (GDGY in GFB-111; GKGK in GFB-
116) in combination with the calix[4]arene scaffold used here
(four “Tyr-like” aromatic rings) highlights the crucial presence
of aromatic and acidic or basic residues (16, 17). Moreover,
many of these systems may also involve structurally ill defined
FIGURE 5.SPRbinding studieswithCDR-derivedpeptidomimetics.A, SPR curves (%Rmax versus time, being 100%RmaxwhenReqRmax,calc) for G17binding
of 50M bicyclic peptidomimetics 1d and 1h, tricyclic mimetics 2a and 2b, and linear control 5c, all derived frommAb 189DB3. B, SPR curves for G17 binding
of bicyclic peptidomimetics derived from scFv PAR10C3 (1n/1o), scFv PAR10D10 (1p/1q), anti-egg white lysozyme mAb D1.3 (1s), and random bicyclic
mimetics 1v and 1w.
FIGURE 6. G17 neutralization studies with CDR-derived peptidomimetics in comparison with anti-G17 scFvs and mAbs. A and C, G17-neutralizing
activities of 189DB3-derived bicyclic mimetics 1d/1h, tricyclic mimetics 2a/2b, monocyclic mimetics 3a/3b, cyclic T3-less mimetic 4a, and linear mimetic 5 at
five different concentrations (200–12.5 M) using Gonadotropin-releasing hormone-derived bicyclic peptidomimetic 1x (4 charge) as negative control.
B and D, G17 neutralizing activities of anti-G17 scFv and mAbs at five different concentrations (1.6–0.1 M) using anti-GST mAb as negative control. G17
neutralization studies BxPc3 (A and B) andColo320WT cell-basedbioassays (C andD). Media and standard deviation of the assays are represented in the figure.
B and D, data were adapted from Refs. 35, 36.
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complexes that are multivalent in nature. So far, the molecular
structure of complexes resolved by x-ray or NMR has not been
reported, which supports this view. Regarding the close analogy
between these systems and the one described here, it is likely
that similar binding mechanisms apply. The assumption that
stable complexes reflect high affinity 1:1 interactions might
lead to the incorrect conclusion that such mimics are indeed
very good representatives of the parent antibodies (18).
In summary, we report the first example of CDR-derived
peptidomimetics with neutralizing and in vitro anti-tumoral
activity. The synthetically derived peptidomimetics were
extremely effective in their gastrin neutralizing activity, despite
their relative low affinity. IC50 values were only 30-fold higher
(50 versus 1.6 M) than for the most active high affinity mAbs
(243BA5 and 198CA8) (35). However, our studies revealed
essential differences in their binding. Given that the high
throughput screening procedure will likely select affinity con-
tributions of low specificity (hydrophobic and electrostatic
interactions), itmay be desirable to focus in consecutive rounds
on specificity-enhancing modifications. CDR sequences might
be regarded as a good starting point but by no means should be
considered an end point. The results described in this study
provide a useful new tool for future design of antibodymimetics
and pave theway to their clinical application in the treatment of
pancreatic and other gastric tumors.
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